Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis
| العنوان: | Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis |
|---|---|
| المؤلفون: | Ciarán M. Duffy, Bianca Lang, Suzanne E. Ramsey, Alma Bencivenga, Deborah M. Levy, Ronald M. Laxer, Adam M. Huber, Paivi Miettunen, Rae S. M. Yeung, Anne-Laure Chetaille, Natalie J. Shiff, Rosie Scuccimarri, Gaëlle Chédeville, Elizabeth Stringer, Karen Watanabe Duffy, Rayfel Schneider, Lori B. Tucker, Claire LeBlanc, Kiem Oen, David A. Cabral, Paul Dancey, Alan M. Rosenberg, Nicole Johnson, Johannes Roth, Sarah Campillo, Susanne M. Benseler, Shirley M. L. Tse, Peter B. Dent, Heinrike Schmeling, Elie Haddad |
| المصدر: | The Journal of Rheumatology. 39:1875-1879 |
| بيانات النشر: | The Journal of Rheumatology, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Male, Canada, medicine.medical_specialty, Immunology, Alternative medicine, MEDLINE, Arthritis, Severity of Illness Index, Health Services Accessibility, Etanercept, Rheumatology, Severity of illness, medicine, Humans, Immunology and Allergy, Formulary, Child, Intensive care medicine, Reimbursement, Biological Products, business.industry, Abatacept, medicine.disease, Arthritis, Juvenile, Antirheumatic Agents, Health Care Surveys, Physical therapy, Female, business, medicine.drug |
| الوصف: | Objective.To compare access to biologic therapies for children with juvenile idiopathic arthritis (JIA) across Canada, and to identify differences in provincial regulations and criteria for access.Methods.Between June and August 2010, we compiled the provincial guidelines for reimbursement of biologic drugs for children with JIA and conducted a multicenter Canada-wide survey of pediatric rheumatologists to determine their experience with accessing biologic therapies for their patients.Results.There were significant difficulties accessing biologic treatments other than etanercept and abatacept for children. There were large discrepancies in the access criteria and coverage of biologic agents across provinces, notably with age restrictions for younger children.Conclusion.Canadian children with JIA may not receive optimal internationally recognized “standard” care because pediatric coverage for biologic drugs through provincial formularies is limited and inconsistent across the country. There is urgent need for public policy to improve access to biologic therapies for these children to ensure optimal short-term and longterm health outcomes. |
| تدمد: | 1499-2752 0315-162X |
| DOI: | 10.3899/jrheum.120089 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::858f930e15c57b329c3fa8e7b5d1632c https://doi.org/10.3899/jrheum.120089 |
| رقم الانضمام: | edsair.doi.dedup.....858f930e15c57b329c3fa8e7b5d1632c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14992752 0315162X |
|---|---|
| DOI: | 10.3899/jrheum.120089 |